Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof

Abstract

Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

1 . Vaccine, characterized in that it comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof.  
     
     
         2 . Vaccine according to  claim 1 , characterized in that the cathelicidin is an animal cathelicidin.  
     
     
         3 . Vaccine according to  claim 2 , characterized in that the cathelicidin is a mouse cathelicidin.  
     
     
         4 . Vaccine according to  claim 3 , characterized in that the mouse cathelicidin derived antimicrobial peptide comprises a sequence according to Seq. ID 1.  
     
     
         5 . Vaccine-according to  claim 2 , characterized in that the cathelicidin is a human cathelicidin.  
     
     
         6 . Vaccine according to  claim 5 , characterized in that the human cathelicidin derived antimicrobial peptide comprises a sequence according to Seq. ID 2.  
     
     
         7 . Vaccine according to  claim 2 , characterized in that the animal cathelicidin derived antimicrobial peptide is an indolicidin peptide.  
     
     
         8 . Vaccine according to  claim 7 , characterized in that the indolicidin peptide is a bovine indolicidin peptide.  
     
     
         9 . Vaccine according to  claim 8 , characterized in that the bovine indolicidin peptide comprises a sequence according to Seq. ID 3.  
     
     
         10 . Vaccine according to  claim 2 , characterized in that the animal cathelicidin derived antimicrobial peptide is a bovine cyclized and/or linear dodecapeptide comprising a sequence according to Seq. ID 4.  
     
     
         11 . Vaccine according to any one of  claims 1  to  10 , characterized in that it comprises at least one further immune response stimulating substance.  
     
     
         12 . Vaccine according to  claim 11 , characterized in that the immune response stimulating substance is a cytokine.  
     
     
         13 . The use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.  
     
     
         14 . The use according to  claim 13 , characterized in that the adjuvant enhances the uptake of at least one antigen in antigen presenting cells (APC).  
     
     
         15 . The use according to  claim 13  or  14 , characterized in that the cathelicidin is an animal cathelicidin.  
     
     
         16 . The use according to  claim 15 , characterized in that the cathelicidin is a mouse cathelicidin.  
     
     
         17 . The use according to  claim 16 , characterized in that the cathelicidin derived antimicrobial peptide comprises a sequence according to Seq. ID 1.  
     
     
         18 . The use according to  claim 15 , characterized in that the ax ) cathelicidin is a human cathelicidin.  
     
     
         19 . The use according to  claim 18 , characterized in that the cathelicidin derived antimicrobial peptide comprises a sequence according to Seq. ID 2.  
     
     
         20 . The use according to  claim 15 , characterized in that the cathelicidin derived antimicrobial peptide is an indolicidin peptide.  
     
     
         21 . The use according to  claim 20 , characterized in that the cathelicidin derived antimicrobial peptide is a bovine indolicidin peptide.  
     
     
         22 . The use according to  claim 21 , characterized in that the cathelicidin derived antimicrobial peptide comprises a sequence according to Seq. ID 3.  
     
     
         23 . The use according to  claim 15 , characterized in that the cathelicidin derived antimicrobial peptide is a bovine cyclized and/or linear dodecapeptide comprising a sequence according to Seq. ID 4.  
     
     
         24 . The use according to one of  claims 13  to  23 , characterized in that the adjuvant is added to a vaccine.